Olaf Kelber
Research Subjects
Olaf Kelber has a total of 959 co-authors. Here are the top co-authors by number of shared publications:
D. Weiser
16 shared publicationsDieter Weiser
Innovation and Development, Phytomedicine Supply and Development Centre, Bayer Consumer Health Care, Steigerwald Arzneimittel GmbH, Havelstraße 5, 64295 Darmstadt, Germany
16 shared publications- Heba Abdel-Aziz
Phytomedicines Supply and Development Center, Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany
10 shared publications Karin Kraft
Naturopathy, Center for Internal Medicine,University of Medicine,Rostock,Germany
9 shared publications- Heba Abdel-Aziz
Scientific Department, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany
8 shared publications - Gudrun Ulrich-Merzenich
Medical Policlinic of the Rheinische Friedrich-Wilhelms-University of Bonn, Wilhelmstr. 35-37, D-53111 Bonn, Germany
7 shared publications
Latest Publications
- 11 November 2025
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 92 (06) , 639-646
Genotoxicity Assessment of Hypericum perforatum Dry Extracts in the Ames Test Based on the “Bracketing and Matrixing” Concept
HMPs derived from Hypericum perforatum, herba (St. Johnʼs wort) play an important role in treating mild to moderate depressive episodes and mental exhaustion, for example. The genotoxic safety of these HMPs has already been assessed and reviewed in recent years. However, further data on the genotoxic potential of Hypericum perforatum, herba preparations would allow the evaluation of the therapeutic safety of the herbal drug and preparations thereof in accordance with the genotoxicity guideline of the HMPC of the EMA. Accordingly, their genotoxic potential was tested using the “bracketing and matrixing” concept, whereby extracts are tested at and between the extremes of their extraction solvents (ranging in strength from polar to non-polar) to cover the entire spectrum of the drugʼs constituents. In the present study, five dry extracts of Hypericum perforatum, herba, representing the full range of potential extraction solvent polarities (water, ethanol 50% (v/v), methanol 80% (v/v), ethanol 80% (v/v), and n-heptane) were tested using the Ames test, according to the OECD and HMPC guidelines. No mutagenic effects were observed for any of the five test strains in two independent experiments (plate incorporation test and pre-incubation test) each carried out with and without metabolic activation, even at the highest concentrations (5000 µg/plate), in accordance with the OECD guideline No. 471.
- 11 November 2025
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 92 (06) , 639-646
Genotoxicity Assessment of Hypericum perforatum Dry Extracts in the Ames Test Based on the “Bracketing and Matrixing” Concept
HMPs derived from Hypericum perforatum, herba (St. Johnʼs wort) play an important role in treating mild to moderate depressive episodes and mental exhaustion, for example. The genotoxic safety of these HMPs has already been assessed and reviewed in recent years. However, further data on the genotoxic potential of Hypericum perforatum, herba preparations would allow the evaluation of the therapeutic safety of the herbal drug and preparations thereof in accordance with the genotoxicity guideline of the HMPC of the EMA. Accordingly, their genotoxic potential was tested using the “bracketing and matrixing” concept, whereby extracts are tested at and between the extremes of their extraction solvents (ranging in strength from polar to non-polar) to cover the entire spectrum of the drugʼs constituents. In the present study, five dry extracts of Hypericum perforatum, herba, representing the full range of potential extraction solvent polarities (water, ethanol 50% (v/v), methanol 80% (v/v), ethanol 80% (v/v), and n-heptane) were tested using the Ames test, according to the OECD and HMPC guidelines. No mutagenic effects were observed for any of the five test strains in two independent experiments (plate incorporation test and pre-incubation test) each carried out with and without metabolic activation, even at the highest concentrations (5000 µg/plate), in accordance with the OECD guideline No. 471.
- 21 October 2024
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 45 (05) , 198-201
Leitlinie ICH E11A veröffentlicht
Zusammenfassung: Die Ausweitung der Zulassung bzw. Registrierung pflanzlicher Arzneimittel auch auf Kinder ist in den letzten Jahren zunehmend herausfordernder geworden. Daher gibt es Initiativen wissenschaftlicher Fachgesellschaften, diese dadurch zu erleichtern, dass sie sich zukünftig auch auf Real World Data (RWD) stützen kann. Im Rahmen der deutschen Nachzulassung und der Erstellung verschiedener HMPC-Monografien hat sich ein solches Vorgehen schon bewährt. Die neue Leitlinie ICH E11A zur Extrapolation von an Erwachsenen gewonnenen Daten auf Kinder hebt zwar stark auf die Nutzung von Pharmakokinetikdaten für die Extrapolation ab, die bei pflanzlichen Arzneimitteln in der Regel nicht aussagekräftig sind. Doch ist die Leitlinie grundsätzlich auch für andere Wege der Extrapolation einschließlich RWE offen, soweit diese geeignet sind, die Zulassungsbehörden zu überzeugen.
- 21 October 2024
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 45 (05) , 198-201
Leitlinie ICH E11A veröffentlicht
Zusammenfassung: Die Ausweitung der Zulassung bzw. Registrierung pflanzlicher Arzneimittel auch auf Kinder ist in den letzten Jahren zunehmend herausfordernder geworden. Daher gibt es Initiativen wissenschaftlicher Fachgesellschaften, diese dadurch zu erleichtern, dass sie sich zukünftig auch auf Real World Data (RWD) stützen kann. Im Rahmen der deutschen Nachzulassung und der Erstellung verschiedener HMPC-Monografien hat sich ein solches Vorgehen schon bewährt. Die neue Leitlinie ICH E11A zur Extrapolation von an Erwachsenen gewonnenen Daten auf Kinder hebt zwar stark auf die Nutzung von Pharmakokinetikdaten für die Extrapolation ab, die bei pflanzlichen Arzneimitteln in der Regel nicht aussagekräftig sind. Doch ist die Leitlinie grundsätzlich auch für andere Wege der Extrapolation einschließlich RWE offen, soweit diese geeignet sind, die Zulassungsbehörden zu überzeugen.
- Open Access
Medicinal Plants and Their Impact on the Gut Microbiome in Mental Health: A Systematic Review
Background: Various neurocognitive and mental health-related conditions have been associated with the gut microbiome, implicating a microbiome–gut–brain axis (MGBA). The aim of this systematic review was to identify, categorize, and review clinical evidence supporting medicinal plants for the treatment of mental disorders and studies on their interactions with the gut microbiota. Methods: This review included medicinal plants for which clinical studies on depression, sleeping disorders, anxiety, or cognitive dysfunction as well as scientific evidence of interaction with the gut microbiome were available. The studies were reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results: Eighty-five studies met the inclusion criteria and covered thirty mental health-related medicinal plants with data on interaction with the gut microbiome. Conclusion: Only a few studies have been specifically designed to assess how herbal preparations affect MGBA-related targets or pathways. However, many studies provide hints of a possible interaction with the MGBA, such as an increased abundance of health-beneficial microorganisms, anti-inflammatory effects, or MGBA-related pathway effects by gut microbial metabolites. Data for Panax ginseng, Schisandra chinensis, and Salvia rosmarinus indicate that the interaction of their constituents with the gut microbiota could mediate mental health benefits. Studies specifically assessing the effects on MGBA-related pathways are still required for most medicinal plants.
Open AccessMedicinal Plants and Their Impact on the Gut Microbiome in Mental Health: A Systematic Review
Background: Various neurocognitive and mental health-related conditions have been associated with the gut microbiome, implicating a microbiome–gut–brain axis (MGBA). The aim of this systematic review was to identify, categorize, and review clinical evidence supporting medicinal plants for the treatment of mental disorders and studies on their interactions with the gut microbiota. Methods: This review included medicinal plants for which clinical studies on depression, sleeping disorders, anxiety, or cognitive dysfunction as well as scientific evidence of interaction with the gut microbiome were available. The studies were reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results: Eighty-five studies met the inclusion criteria and covered thirty mental health-related medicinal plants with data on interaction with the gut microbiome. Conclusion: Only a few studies have been specifically designed to assess how herbal preparations affect MGBA-related targets or pathways. However, many studies provide hints of a possible interaction with the MGBA, such as an increased abundance of health-beneficial microorganisms, anti-inflammatory effects, or MGBA-related pathway effects by gut microbial metabolites. Data for Panax ginseng, Schisandra chinensis, and Salvia rosmarinus indicate that the interaction of their constituents with the gut microbiota could mediate mental health benefits. Studies specifically assessing the effects on MGBA-related pathways are still required for most medicinal plants.
- 15 March 2022
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 43 (01) , 9-13
Bidirektionale Wechselwirkungen zwischen pflanzlichen Arzneimitteln und dem Darmmikrobiom: Neue Forschungsansätze
Das menschliche Darmmikrobiom ist ein komplexes Ökosystem, in dem Milliarden von Mikroorganismen koexistieren. Es ist von Bakterien dominiert, umfasst aber auch Archaeen, Pilze, Protozoen, Eukaryoten und Viren. Am häufigsten sind die beiden bakteriellen Phylotypen Bacteroides und Firmicutes. Die anderen Stämme, Proteobakterien, Actinobakterien, Fusobakterien und Verrucomicrobia, sind vergleichsweise weniger häufig [11]. Die Zusammensetzung des Darmmikrobioms weist große individuelle Unterschiede auf und wird durch viele Faktoren beeinflusst, zum Beispiel Alter, Gesundheitszustand, Medikamente, Ernährung, Lebensumfeld und die Art der Geburt [9]. Das Darmmikrobiom hat viele wichtigen Funktionen, auch über den Stoffwechsel im engeren Sinne hinaus. Es wirkt bei der Metabolisierung von Nahrungsbestandteilen, aber auch pflanzlichen und anderen Wirkstoffen mit und kann so die Aufnahme von Nährstoffen, Mineralien und Vitaminen aus der Nahrung erleichtern, essenzielle Vitamine synthetisieren und bestimmte Neurotransmitter und Hormone metabolisieren [18]. Das Darmmikrobiom verfügt über ein breiteres Spektrum an metabolischen Enzymen als der Mensch selbst, sein Stoffwechsel ist daher leistungsfähiger. Zudem kann es das angeborene und das adaptive Immunsystem des Menschen modulieren und ihn so, als eine erste Verteidigungslinie, vor Krankheitserregern schützen [24]. Zahlreiche Studien haben aber auch gezeigt, dass Lebensmittel und Medikamente, einschließlich der pflanzlichen Arzneimittel, die Zusammensetzung und Funktion des Darmmikrobioms signifikant beeinflussen können [1] [25]. Die vom Darmmikrobiom gebildeten Metabolite werden in drei Gruppen eingeteilt [16]: Pflanzliche Arzneimittel sind eine komplexe Mischung aus Produkten des pflanzlichen Primärstoffwechsels, zu denen z. B. die komplexen Kohlenhydrate zählen, als auch des pflanzlichen Sekundärstoffwechsels, darunter Polyphenole, Alkaloide und Terpenglykoside. Viele dieser Naturstoffe können durch die Enzyme des oberen Darmtraktes nicht metabolisiert, aber aufgrund ihres hohen Molekulargewichts oder ihrer hohen Polarität auch nur schlecht resorbiert werden. Sie passieren daher den Dünndarm, dessen mikrobielle Besiedelung relativ spärlich und auf den Metabolismus von einfachen Zuckern spezialisiert ist, erreichen den Dickdarm und kommen mit dessen sehr vielfältigen Mikrobiom in Kontakt. Dieses besitzt eine enorme Stoffwechselkapazität und bildet aus vielen dieser pflanzlichen Inhaltsstoffe neue Metabolite, von denen etliche eine bessere Bioverfügbarkeit und eine bessere pharmakologische Aktivität besitzen als ihre Vorläuferverbindungen. Viele dieser Metaboliten spielen daher eine wichtige Rolle bei der gesundheitsfördernden Wirkung von pflanzlichen Arzneimitteln ([Tab. 1]). Die pflanzlichen Inhaltsstoffe können aber auch die Zusammensetzung und Funktion des Darmmikrobioms und dessen metabolische Kapazität modulieren [19]. Dies gilt für bekannte Präbiotika wie das komplexe Kohlenhydrat Inulin, das zu gesundheitsfördernden kurzkettigen Fettsäuren (SCFAs) fermentiert wird und die Häufigkeit von Bifidobakterien im menschlichen Darm erhöht [12]. Anti- und präbiotische und damit gesundheitsfördernde Wirkungen wurden auch für sekundäre Pflanzeninhaltsstoffe wie Phenole und Terpene beschrieben [1] ([Abb. 1]). In den letzten zehn Jahren war der Fokus der meisten Studien zu pflanzlichen Arzneimitteln und Darmmikrobiota entweder auf deren Wirkung auf das Darmmikrobiom gerichtet, oder auf die durch das Mikrobiom gebildeten Metaboliten [20]. Inzwischen gibt es aber zunehmend Studien, in denen beides untersucht wird. Hierfür stehen verschiedene methodische Ansätze in vitro und in vivo zur Verfügung. Publication Date: 15 March 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 15 March 2022
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 43 (01) , 9-13
Bidirektionale Wechselwirkungen zwischen pflanzlichen Arzneimitteln und dem Darmmikrobiom: Neue Forschungsansätze
Das menschliche Darmmikrobiom ist ein komplexes Ökosystem, in dem Milliarden von Mikroorganismen koexistieren. Es ist von Bakterien dominiert, umfasst aber auch Archaeen, Pilze, Protozoen, Eukaryoten und Viren. Am häufigsten sind die beiden bakteriellen Phylotypen Bacteroides und Firmicutes. Die anderen Stämme, Proteobakterien, Actinobakterien, Fusobakterien und Verrucomicrobia, sind vergleichsweise weniger häufig [11]. Die Zusammensetzung des Darmmikrobioms weist große individuelle Unterschiede auf und wird durch viele Faktoren beeinflusst, zum Beispiel Alter, Gesundheitszustand, Medikamente, Ernährung, Lebensumfeld und die Art der Geburt [9]. Das Darmmikrobiom hat viele wichtigen Funktionen, auch über den Stoffwechsel im engeren Sinne hinaus. Es wirkt bei der Metabolisierung von Nahrungsbestandteilen, aber auch pflanzlichen und anderen Wirkstoffen mit und kann so die Aufnahme von Nährstoffen, Mineralien und Vitaminen aus der Nahrung erleichtern, essenzielle Vitamine synthetisieren und bestimmte Neurotransmitter und Hormone metabolisieren [18]. Das Darmmikrobiom verfügt über ein breiteres Spektrum an metabolischen Enzymen als der Mensch selbst, sein Stoffwechsel ist daher leistungsfähiger. Zudem kann es das angeborene und das adaptive Immunsystem des Menschen modulieren und ihn so, als eine erste Verteidigungslinie, vor Krankheitserregern schützen [24]. Zahlreiche Studien haben aber auch gezeigt, dass Lebensmittel und Medikamente, einschließlich der pflanzlichen Arzneimittel, die Zusammensetzung und Funktion des Darmmikrobioms signifikant beeinflussen können [1] [25]. Die vom Darmmikrobiom gebildeten Metabolite werden in drei Gruppen eingeteilt [16]: Pflanzliche Arzneimittel sind eine komplexe Mischung aus Produkten des pflanzlichen Primärstoffwechsels, zu denen z. B. die komplexen Kohlenhydrate zählen, als auch des pflanzlichen Sekundärstoffwechsels, darunter Polyphenole, Alkaloide und Terpenglykoside. Viele dieser Naturstoffe können durch die Enzyme des oberen Darmtraktes nicht metabolisiert, aber aufgrund ihres hohen Molekulargewichts oder ihrer hohen Polarität auch nur schlecht resorbiert werden. Sie passieren daher den Dünndarm, dessen mikrobielle Besiedelung relativ spärlich und auf den Metabolismus von einfachen Zuckern spezialisiert ist, erreichen den Dickdarm und kommen mit dessen sehr vielfältigen Mikrobiom in Kontakt. Dieses besitzt eine enorme Stoffwechselkapazität und bildet aus vielen dieser pflanzlichen Inhaltsstoffe neue Metabolite, von denen etliche eine bessere Bioverfügbarkeit und eine bessere pharmakologische Aktivität besitzen als ihre Vorläuferverbindungen. Viele dieser Metaboliten spielen daher eine wichtige Rolle bei der gesundheitsfördernden Wirkung von pflanzlichen Arzneimitteln ([Tab. 1]). Die pflanzlichen Inhaltsstoffe können aber auch die Zusammensetzung und Funktion des Darmmikrobioms und dessen metabolische Kapazität modulieren [19]. Dies gilt für bekannte Präbiotika wie das komplexe Kohlenhydrat Inulin, das zu gesundheitsfördernden kurzkettigen Fettsäuren (SCFAs) fermentiert wird und die Häufigkeit von Bifidobakterien im menschlichen Darm erhöht [12]. Anti- und präbiotische und damit gesundheitsfördernde Wirkungen wurden auch für sekundäre Pflanzeninhaltsstoffe wie Phenole und Terpene beschrieben [1] ([Abb. 1]). In den letzten zehn Jahren war der Fokus der meisten Studien zu pflanzlichen Arzneimitteln und Darmmikrobiota entweder auf deren Wirkung auf das Darmmikrobiom gerichtet, oder auf die durch das Mikrobiom gebildeten Metaboliten [20]. Inzwischen gibt es aber zunehmend Studien, in denen beides untersucht wird. Hierfür stehen verschiedene methodische Ansätze in vitro und in vivo zur Verfügung. Publication Date: 15 March 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 January 2021
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 861-862, 503305
Genotoxicity of selected pyrrolizidine alkaloids in human hepatoma cell lines HepG2 and Huh6
- 1 January 2021
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 861-862, 503305
Genotoxicity of selected pyrrolizidine alkaloids in human hepatoma cell lines HepG2 and Huh6
- Open Access
- 11 December 2019
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 179 (3) , 507-512
Pharmaco-epidemiological research on herbal medicinal products in the paediatric population: data from the PhytoVIS study
In paediatrics, clinical study data are limited, especially on herbal medicinal products. To address this gap, 2063 datasets from the paediatric population were evaluated in the PhytoVIS data base. By screening for paediatric data, information on indication, gender, treatment, co-medication and tolerability were evaluated. The majority of patients was treated because of common cold, fever, digestive complaints, skin diseases, sleep disturbances and anxiety. The perceived effect of the therapy was rated in 84% of the patients as very good or good without adverse events. The data shed light on a still neglected field of phyto-pharmacotherapy by giving information on the use of herbal medicines in an unselected cohort of paediatric patients. The results confirm the good clinical effects and safety of herbal medicinal products in this patient population and show that they are widely used in Germany. What is Known:• In Germany, about 85% of children receive one or more herbal medicinal products per year.• Despite international initiatives to promote clinical research in paediatrics, there are still many gaps of knowledge in the use of drugs in paediatrics. What is New:• The PhytoVIS project evaluated 2063 data sets from the paediatric population using herbal medicinal products.• The majority of patients was treated because of common cold, fever, digestive complaints, skin diseases, sleep disturbances and anxiety, and 84% of the patients rated the therapy as very good or good without adverse events.
- 11 December 2019
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 179 (3) , 507-512
Open AccessPharmaco-epidemiological research on herbal medicinal products in the paediatric population: data from the PhytoVIS study
In paediatrics, clinical study data are limited, especially on herbal medicinal products. To address this gap, 2063 datasets from the paediatric population were evaluated in the PhytoVIS data base. By screening for paediatric data, information on indication, gender, treatment, co-medication and tolerability were evaluated. The majority of patients was treated because of common cold, fever, digestive complaints, skin diseases, sleep disturbances and anxiety. The perceived effect of the therapy was rated in 84% of the patients as very good or good without adverse events. The data shed light on a still neglected field of phyto-pharmacotherapy by giving information on the use of herbal medicines in an unselected cohort of paediatric patients. The results confirm the good clinical effects and safety of herbal medicinal products in this patient population and show that they are widely used in Germany. What is Known:• In Germany, about 85% of children receive one or more herbal medicinal products per year.• Despite international initiatives to promote clinical research in paediatrics, there are still many gaps of knowledge in the use of drugs in paediatrics. What is New:• The PhytoVIS project evaluated 2063 data sets from the paediatric population using herbal medicinal products.• The majority of patients was treated because of common cold, fever, digestive complaints, skin diseases, sleep disturbances and anxiety, and 84% of the patients rated the therapy as very good or good without adverse events.
- Open Access
- 21 October 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 25 (39) , 5926-5935
STW 5 is effective against nonsteroidal anti-inflammatory drugs induced gastro-duodenal lesions in rats
Proton pump inhibitors are often used to prevent gastro-intestinal lesions induced by nonsteroidal anti-inflammatory drugs. However, they are not always effective against both gastric and duodenal lesions and their use is not devoid of side effects. To explore the mechanisms mediating the clinical efficacy of STW 5 in gastro-duodenal lesions induced by nonsteroidal anti-inflammatory drugs (NSAIDs), exemplified here by diclofenac, in a comparison to omeprazole. Gastro-duodenal lesions were induced in rats by oral administration of diclofenac (5 mg/kg) for 6 successive days. One group was given concurrently STW 5 (5 mL/kg) while another was given omeprazole (20 mg/kg). A day later, animals were sacrificed, stomach and duodenum excised and divided into 2 segments: One for histological examination and one for measuring inflammatory mediators (tumor necrosis factor α, interleukins-1β and 10), oxidative stress enzyme (heme oxygenase-1) and apoptosis regulator (B-cell lymphoma 2). Diclofenac caused overt histological damage in both tissues, associated with parallel changes in all parameters measured. STW 5 and omeprazole effectively prevented these changes, but STW 5 superseded omeprazole in protecting against histological damage, particularly in the duodenum. The findings support the therapeutic usefulness of STW 5 and its superiority over omeprazole as adjuvant therapy to NSAIDs to protect against their possible gastro-duodenal side effects.
- 21 October 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 25 (39) , 5926-5935
Open AccessSTW 5 is effective against nonsteroidal anti-inflammatory drugs induced gastro-duodenal lesions in rats
Proton pump inhibitors are often used to prevent gastro-intestinal lesions induced by nonsteroidal anti-inflammatory drugs. However, they are not always effective against both gastric and duodenal lesions and their use is not devoid of side effects. To explore the mechanisms mediating the clinical efficacy of STW 5 in gastro-duodenal lesions induced by nonsteroidal anti-inflammatory drugs (NSAIDs), exemplified here by diclofenac, in a comparison to omeprazole. Gastro-duodenal lesions were induced in rats by oral administration of diclofenac (5 mg/kg) for 6 successive days. One group was given concurrently STW 5 (5 mL/kg) while another was given omeprazole (20 mg/kg). A day later, animals were sacrificed, stomach and duodenum excised and divided into 2 segments: One for histological examination and one for measuring inflammatory mediators (tumor necrosis factor α, interleukins-1β and 10), oxidative stress enzyme (heme oxygenase-1) and apoptosis regulator (B-cell lymphoma 2). Diclofenac caused overt histological damage in both tissues, associated with parallel changes in all parameters measured. STW 5 and omeprazole effectively prevented these changes, but STW 5 superseded omeprazole in protecting against histological damage, particularly in the duodenum. The findings support the therapeutic usefulness of STW 5 and its superiority over omeprazole as adjuvant therapy to NSAIDs to protect against their possible gastro-duodenal side effects.
- 9 September 2019
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 40 (S 01) , V19
Marshmallow root: A medicinal plant with a great tradition
Background and aim: There is an increasing popularity of natural treatment options in patients and consumers worldwide. This is not only true e.g. for Chinese and Indian traditions, but also for European traditions, leading to an increasing use of such products all around the globe [1]. This is also true for root extracts from Marshmallow (Althaea officinalis L.), which are successfully used for maintaining respiratory health resp. in mucosal irritations of the respiratory tract and irritative cough, as new study data show [2, 3], which are therefore of specific interest also from a historical perspective. Methods: Based on textbooks and monographs, cross referencing and hand searching, also via internet, a survey was conducted to retrieve historical texts on its medicinal use. Results: Althea officinalis L. has a wide spread natural range in Eurasia, and nowadays occurs worldwide in temperate climates. While from the early advanced civilizations of the middle east no evidence of its use could be found, it is mentioned in the Greco-Roman literature by Hippokrates of Kos and, among others, the Cilician physician Dioscurides, who mentions its use in anuria, diarrhoea, lithiasis, internal injuries, nerve pain etc. The first clear evidence for its use for the treatment of the respiratory tract is Plinius's Naturalis historia (ca. 77 AD). The plant is then also mentioned in European medieval texts. Paracelsus describes its use as abscess emollient and cleanser [4, 5]. The plant is also mentioned in the pharmacopoeias of the 19th and 20th century, e.g. Deutsches Arzneibuch 1926, British Pharmaceutical Codex 1949 [6, 7] and in medical and pharmaceutical textbooks from that time on, e.g. Madaus 1938, Hänsel et al. 1993, Blaschek 2015 [8 – 10]. In these textbooks also its traditional preparations, i.e. aqueous root macerates, are described. The cough syrup STW 42 is accordingly a typical example complying with this tradition. This is in line with its descriptions in modern European herbal monographs, as those of Commission E, ESCOP and HMPC, which are accepted today as references for its use, also in many non-European countries worldwide. Recent research has proven that this preparation has not only immediate protective physical effects [2, 3, 11], but also beneficial pharmacological effects on the irritated pharyngeal mucosa [12]. Conclusion: For Marshmallow root, a long tradition could be proven, which well supports its use in patients and consumers worldwide, and is an adequate base for its positive image as a plant well supporting respiratory health and offering fast relief in respiratory complaints. Acknowledgement: Many thanks to Florian Eidam-Weber, Frankfurt, for stimulating discussions. References: [1] Kelber. Symposium of Kooperation Phytopharmaka, Köln 2017 [2] Fasse et al. Paed 2005; 11:3 – 8. 4 [3] Fink et al. Complement Med Res 2018; 25: 299 – 305 [4] Benedum et al. Arzneipflanzen in der Traditionellen Medizin. Kooperation Phytopharmaka, 2000 [5] Leonti et al. J Ethnopharmacol 2017; 199: 161 – 167 [6] Deutsches Arzneibuch, R. v. Decker, Ausgabe 6, 1926 [7] British Pharmaceutical Codex, The Pharmaceutical Press, 1949 [8] Madaus. Lehrbuch der biologischen Heilmittel. Georg Thieme Verlag Leipzig, 1938 [9] Hänsel et al. Lehrbuch Phytotherapie. Springer Berlin, 1993 [10] Blaschek. Wichtl – Teedrogen und Phytopharmaka. WVG Stuttgart, 2015 [11] Rouhi and Ganji. Pakistan J Nutr 2007; 6: 256 – 258 [12] Deters et al. J Ethnopharmacol 2010; 127: 62 – 69
- 9 September 2019
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 40 (S 01) , V19
Marshmallow root: A medicinal plant with a great tradition
Background and aim: There is an increasing popularity of natural treatment options in patients and consumers worldwide. This is not only true e.g. for Chinese and Indian traditions, but also for European traditions, leading to an increasing use of such products all around the globe [1]. This is also true for root extracts from Marshmallow (Althaea officinalis L.), which are successfully used for maintaining respiratory health resp. in mucosal irritations of the respiratory tract and irritative cough, as new study data show [2, 3], which are therefore of specific interest also from a historical perspective. Methods: Based on textbooks and monographs, cross referencing and hand searching, also via internet, a survey was conducted to retrieve historical texts on its medicinal use. Results: Althea officinalis L. has a wide spread natural range in Eurasia, and nowadays occurs worldwide in temperate climates. While from the early advanced civilizations of the middle east no evidence of its use could be found, it is mentioned in the Greco-Roman literature by Hippokrates of Kos and, among others, the Cilician physician Dioscurides, who mentions its use in anuria, diarrhoea, lithiasis, internal injuries, nerve pain etc. The first clear evidence for its use for the treatment of the respiratory tract is Plinius's Naturalis historia (ca. 77 AD). The plant is then also mentioned in European medieval texts. Paracelsus describes its use as abscess emollient and cleanser [4, 5]. The plant is also mentioned in the pharmacopoeias of the 19th and 20th century, e.g. Deutsches Arzneibuch 1926, British Pharmaceutical Codex 1949 [6, 7] and in medical and pharmaceutical textbooks from that time on, e.g. Madaus 1938, Hänsel et al. 1993, Blaschek 2015 [8 – 10]. In these textbooks also its traditional preparations, i.e. aqueous root macerates, are described. The cough syrup STW 42 is accordingly a typical example complying with this tradition. This is in line with its descriptions in modern European herbal monographs, as those of Commission E, ESCOP and HMPC, which are accepted today as references for its use, also in many non-European countries worldwide. Recent research has proven that this preparation has not only immediate protective physical effects [2, 3, 11], but also beneficial pharmacological effects on the irritated pharyngeal mucosa [12]. Conclusion: For Marshmallow root, a long tradition could be proven, which well supports its use in patients and consumers worldwide, and is an adequate base for its positive image as a plant well supporting respiratory health and offering fast relief in respiratory complaints. Acknowledgement: Many thanks to Florian Eidam-Weber, Frankfurt, for stimulating discussions. References: [1] Kelber. Symposium of Kooperation Phytopharmaka, Köln 2017 [2] Fasse et al. Paed 2005; 11:3 – 8. 4 [3] Fink et al. Complement Med Res 2018; 25: 299 – 305 [4] Benedum et al. Arzneipflanzen in der Traditionellen Medizin. Kooperation Phytopharmaka, 2000 [5] Leonti et al. J Ethnopharmacol 2017; 199: 161 – 167 [6] Deutsches Arzneibuch, R. v. Decker, Ausgabe 6, 1926 [7] British Pharmaceutical Codex, The Pharmaceutical Press, 1949 [8] Madaus. Lehrbuch der biologischen Heilmittel. Georg Thieme Verlag Leipzig, 1938 [9] Hänsel et al. Lehrbuch Phytotherapie. Springer Berlin, 1993 [10] Blaschek. Wichtl – Teedrogen und Phytopharmaka. WVG Stuttgart, 2015 [11] Rouhi and Ganji. Pakistan J Nutr 2007; 6: 256 – 258 [12] Deters et al. J Ethnopharmacol 2010; 127: 62 – 69
- Open Access
- 1 July 2019
- Published by Elsevier in Phytomedicine
- Vol. 60, 153013
Synergy quantifications to identify individual contributions of combination partners to the overall activity – The example of STW 5
- 1 July 2019
- Published by Elsevier in Phytomedicine
- Vol. 60, 153013
Open AccessSynergy quantifications to identify individual contributions of combination partners to the overall activity – The example of STW 5
- Open Access
- 1 May 2019
- Published by Elsevier in Phytomedicine
- Vol. 58, 152868
Anti-inflammatory effects of Phytodolor® (STW 1) and components (poplar, ash and goldenrod) on human monocytes/macrophages
- 1 May 2019
- Published by Elsevier in Phytomedicine
- Vol. 58, 152868
Open AccessAnti-inflammatory effects of Phytodolor® (STW 1) and components (poplar, ash and goldenrod) on human monocytes/macrophages